Physician profile
Daniel X Yang
NPI 1750818928
$2,404.04
in general payments reported to CMS, 2019-2025
8 companies · $81.82 in 2025
The $81.82 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,421 · 2024: $901 · 2025: $81.82.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,483 · Food and Beverage: $921.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,483.05 |
| Food and Beverage | $920.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Pharmaceuticals, INC. | $1,565.40 | 2023-2024 | |
| Telix Pharmaceuticals | $214.17 | 2024-2025 | Illuccix |
| Reflexion Medical, INC. | $213.00 | 2023 | Reflexion Medical Radiotherapy System |
| Angiodynamics, INC. | $143.08 | 2023 | Nanoknife |
| Blue Earth Diagnostics | $112.00 | 2024 | |
| Johnson & Johnson Health Care Systems INC. | $93.75 | 2023 | Akeega, Erleada |
| Progenics Pharmaceuticals, INC. | $43.71 | 2024 | |
| Boston Scientific Corporation | $18.93 | 2025 | Spaceoar Vue System - 10ml |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Yang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.